CN Stock MarketDetailed Quotes

301211 Hubei Biocause Heilen Pharmaceutical

Watchlist
  • 16.48
  • +0.24+1.48%
Trading Oct 14 13:19 CST
4.75BMarket Cap36.06P/E (TTM)

Hubei Biocause Heilen Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
Total operating revenue
-40.39%241.87M
-28.57%138.06M
28.76%663.03M
56.93%542.45M
68.80%405.76M
50.72%193.29M
-4.76%514.91M
-17.37%345.66M
-13.17%240.38M
6.01%128.25M
Operating revenue
-40.39%241.87M
-28.57%138.06M
28.76%663.03M
56.93%542.45M
68.80%405.76M
50.72%193.29M
-4.76%514.91M
-17.37%345.66M
-13.17%240.38M
6.01%128.25M
Other operating revenue
56.98%3.43M
----
256.20%11.61M
----
177.02%2.19M
----
273.24%3.26M
----
78.67%789.39K
----
Total operating cost
-39.85%164.43M
-34.36%94.97M
24.31%467.72M
42.95%374.33M
51.13%273.39M
45.38%144.69M
-10.97%376.27M
-17.28%261.86M
-13.06%180.9M
16.20%99.53M
Operating cost
-37.05%154.79M
-34.58%85.71M
8.32%396.67M
31.90%321.42M
43.70%245.87M
45.44%131.01M
2.55%366.22M
-8.86%243.68M
-1.73%171.1M
30.79%90.08M
Operating tax surcharges
-29.28%2.2M
-68.57%575.61K
49.40%5.92M
95.91%4.47M
82.02%3.12M
348.40%1.83M
-32.81%3.96M
-10.79%2.28M
12.05%1.71M
-2.56%408.43K
Operating expense
-22.22%10.4M
-10.68%5.88M
61.58%24.08M
26.70%17.47M
44.87%13.37M
2.43%6.58M
24.50%14.91M
64.08%13.79M
68.73%9.23M
34.12%6.43M
Administration expense
1.11%19.23M
-1.57%9.6M
6.35%38.89M
-5.53%35.34M
-16.99%19.02M
-16.91%9.76M
31.66%36.56M
52.66%37.41M
31.73%22.91M
33.55%11.74M
Financial expense
-47.06%-41.49M
-52.82%-17.74M
22.40%-50.62M
22.03%-39.3M
16.17%-28.21M
15.59%-11.61M
-4,199.45%-65.23M
-3,900.52%-50.4M
-2,046.11%-33.65M
-5,062.58%-13.75M
-Interest expense (Financial expense)
-6.24%125.05K
6.01%63.25K
-10.74%307.43K
--203.66K
--133.38K
--59.67K
--344.41K
----
----
----
-Interest Income (Financial expense)
-60.99%-39.58M
-39.13%-17.11M
21.60%-47.84M
21.14%-36.29M
19.99%-24.58M
15.27%-12.3M
-2,445.56%-61.02M
-38,070.13%-46.02M
-29,782.57%-30.72M
-74,392.38%-14.51M
Research and development
-4.55%19.3M
53.73%10.94M
165.94%52.77M
131.24%34.93M
110.62%20.21M
53.89%7.12M
8.55%19.84M
21.91%15.11M
22.16%9.6M
51.84%4.63M
Credit Impairment Loss
18.64%-614.54K
-177.21%-326.5K
-65.28%596.61K
-101.87%-32.87K
-157.73%-755.38K
-56.82%422.85K
268.49%1.72M
300.05%1.76M
362.69%1.31M
576.64%979.24K
Asset Impairment Loss
----
----
----
---1.53M
---1.53M
---1.53M
----
----
----
----
Other net revenue
159.87%3.7M
359.12%1.26M
-0.51%10.03M
-68.91%3.05M
-76.03%1.42M
-109.45%-484.46K
-52.66%10.08M
-22.22%9.81M
-21.59%5.93M
15.08%5.13M
Fair value change income
--2.65M
--947.92K
--4.02M
----
----
----
----
----
----
----
Invest income
--975.1K
--34.44K
----
----
----
----
----
----
----
----
Asset deal income
----
----
327.18%177.18K
-106.93%-2.88K
-151.84%-2.88K
----
156.60%41.48K
162.35%41.48K
107.57%5.55K
----
Other revenue
-81.53%684.82K
-3.33%599.48K
-37.08%5.24M
-42.42%4.61M
-19.73%3.71M
-85.05%620.11K
-28.78%8.32M
26.26%8.01M
50.75%4.62M
268.65%4.15M
Operating profit
-39.36%81.13M
-7.84%44.34M
38.06%205.33M
82.86%171.17M
104.54%133.79M
42.15%48.11M
6.78%148.73M
-18.18%93.61M
-14.28%65.41M
-14.91%33.85M
Add:Non operating Income
145.98%84.43K
790.36%52.08K
--299.28K
197.10%189.3K
-32.46%34.32K
--5.85K
----
3,414.89%63.72K
2,703.29%50.82K
----
Less:Non operating expense
83.21%329.03K
-61.43%69.25K
119.49%2.82M
434.93%570.82K
71.69%179.59K
74.51%179.57K
802.76%1.28M
-28.01%106.71K
4,321.53%104.6K
--102.9K
Total profit
-39.48%80.89M
-7.54%44.32M
37.56%202.82M
82.53%170.79M
104.49%133.65M
42.07%47.94M
5.93%147.44M
-18.11%93.56M
-14.35%65.36M
-15.17%33.74M
Less:Income tax cost
-39.88%12.39M
-13.39%6.94M
23.33%26.7M
75.00%26.27M
88.07%20.61M
38.72%8.02M
23.46%21.65M
0.74%15.01M
31.88%10.96M
77.91%5.78M
Net profit
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
-23.45%27.96M
Net profit from continuing operation
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
-23.45%27.96M
Net profit of parent company owners
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
-23.45%27.96M
Earning per share
Basic earning per share
-38.46%0.24
-7.14%0.13
38.64%0.61
85.19%0.5
105.26%0.39
16.67%0.14
-35.29%0.44
-50.91%0.27
-50.00%0.19
-40.00%0.12
Diluted earning per share
-38.46%0.24
-7.14%0.13
38.64%0.61
85.19%0.5
105.26%0.39
16.67%0.14
-35.29%0.44
-50.91%0.27
-50.00%0.19
-40.00%0.12
Other composite income
Total composite income
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
-23.45%27.96M
Total composite income of parent company owners
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
-23.45%27.96M
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
--
Unqualified opinion
--
--
--
Unqualified opinion
--
--
--
Auditor
--
--
Daishin Certified Public Accountants (Special General Partnership)
--
--
--
Daishin Certified Public Accountants (Special General Partnership)
--
--
--
(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022
Total operating revenue -40.39%241.87M-28.57%138.06M28.76%663.03M56.93%542.45M68.80%405.76M50.72%193.29M-4.76%514.91M-17.37%345.66M-13.17%240.38M6.01%128.25M
Operating revenue -40.39%241.87M-28.57%138.06M28.76%663.03M56.93%542.45M68.80%405.76M50.72%193.29M-4.76%514.91M-17.37%345.66M-13.17%240.38M6.01%128.25M
Other operating revenue 56.98%3.43M----256.20%11.61M----177.02%2.19M----273.24%3.26M----78.67%789.39K----
Total operating cost -39.85%164.43M-34.36%94.97M24.31%467.72M42.95%374.33M51.13%273.39M45.38%144.69M-10.97%376.27M-17.28%261.86M-13.06%180.9M16.20%99.53M
Operating cost -37.05%154.79M-34.58%85.71M8.32%396.67M31.90%321.42M43.70%245.87M45.44%131.01M2.55%366.22M-8.86%243.68M-1.73%171.1M30.79%90.08M
Operating tax surcharges -29.28%2.2M-68.57%575.61K49.40%5.92M95.91%4.47M82.02%3.12M348.40%1.83M-32.81%3.96M-10.79%2.28M12.05%1.71M-2.56%408.43K
Operating expense -22.22%10.4M-10.68%5.88M61.58%24.08M26.70%17.47M44.87%13.37M2.43%6.58M24.50%14.91M64.08%13.79M68.73%9.23M34.12%6.43M
Administration expense 1.11%19.23M-1.57%9.6M6.35%38.89M-5.53%35.34M-16.99%19.02M-16.91%9.76M31.66%36.56M52.66%37.41M31.73%22.91M33.55%11.74M
Financial expense -47.06%-41.49M-52.82%-17.74M22.40%-50.62M22.03%-39.3M16.17%-28.21M15.59%-11.61M-4,199.45%-65.23M-3,900.52%-50.4M-2,046.11%-33.65M-5,062.58%-13.75M
-Interest expense (Financial expense) -6.24%125.05K6.01%63.25K-10.74%307.43K--203.66K--133.38K--59.67K--344.41K------------
-Interest Income (Financial expense) -60.99%-39.58M-39.13%-17.11M21.60%-47.84M21.14%-36.29M19.99%-24.58M15.27%-12.3M-2,445.56%-61.02M-38,070.13%-46.02M-29,782.57%-30.72M-74,392.38%-14.51M
Research and development -4.55%19.3M53.73%10.94M165.94%52.77M131.24%34.93M110.62%20.21M53.89%7.12M8.55%19.84M21.91%15.11M22.16%9.6M51.84%4.63M
Credit Impairment Loss 18.64%-614.54K-177.21%-326.5K-65.28%596.61K-101.87%-32.87K-157.73%-755.38K-56.82%422.85K268.49%1.72M300.05%1.76M362.69%1.31M576.64%979.24K
Asset Impairment Loss ---------------1.53M---1.53M---1.53M----------------
Other net revenue 159.87%3.7M359.12%1.26M-0.51%10.03M-68.91%3.05M-76.03%1.42M-109.45%-484.46K-52.66%10.08M-22.22%9.81M-21.59%5.93M15.08%5.13M
Fair value change income --2.65M--947.92K--4.02M----------------------------
Invest income --975.1K--34.44K--------------------------------
Asset deal income --------327.18%177.18K-106.93%-2.88K-151.84%-2.88K----156.60%41.48K162.35%41.48K107.57%5.55K----
Other revenue -81.53%684.82K-3.33%599.48K-37.08%5.24M-42.42%4.61M-19.73%3.71M-85.05%620.11K-28.78%8.32M26.26%8.01M50.75%4.62M268.65%4.15M
Operating profit -39.36%81.13M-7.84%44.34M38.06%205.33M82.86%171.17M104.54%133.79M42.15%48.11M6.78%148.73M-18.18%93.61M-14.28%65.41M-14.91%33.85M
Add:Non operating Income 145.98%84.43K790.36%52.08K--299.28K197.10%189.3K-32.46%34.32K--5.85K----3,414.89%63.72K2,703.29%50.82K----
Less:Non operating expense 83.21%329.03K-61.43%69.25K119.49%2.82M434.93%570.82K71.69%179.59K74.51%179.57K802.76%1.28M-28.01%106.71K4,321.53%104.6K--102.9K
Total profit -39.48%80.89M-7.54%44.32M37.56%202.82M82.53%170.79M104.49%133.65M42.07%47.94M5.93%147.44M-18.11%93.56M-14.35%65.36M-15.17%33.74M
Less:Income tax cost -39.88%12.39M-13.39%6.94M23.33%26.7M75.00%26.27M88.07%20.61M38.72%8.02M23.46%21.65M0.74%15.01M31.88%10.96M77.91%5.78M
Net profit -39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M-23.45%27.96M
Net profit from continuing operation -39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M-23.45%27.96M
Net profit of parent company owners -39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M-23.45%27.96M
Earning per share
Basic earning per share -38.46%0.24-7.14%0.1338.64%0.6185.19%0.5105.26%0.3916.67%0.14-35.29%0.44-50.91%0.27-50.00%0.19-40.00%0.12
Diluted earning per share -38.46%0.24-7.14%0.1338.64%0.6185.19%0.5105.26%0.3916.67%0.14-35.29%0.44-50.91%0.27-50.00%0.19-40.00%0.12
Other composite income
Total composite income -39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M-23.45%27.96M
Total composite income of parent company owners -39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M-23.45%27.96M
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions ----Unqualified opinion------Unqualified opinion------
Auditor ----Daishin Certified Public Accountants (Special General Partnership)------Daishin Certified Public Accountants (Special General Partnership)------

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
% Chg

No Data